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Abstract
Background: Celastrol is a natural proteasome inhibitor that exhibits promising anti-tumor effects in human malignancies,
especially the androgen-independent prostate cancer (AIPC) with constitutive NF-kB activation. Celastrol induces apoptosis
by means of proteasome inhibition and suppresses prostate tumor growth. However, the detailed mechanism of action
remains elusive. In the current study, we aim to test the hypothesis that celastrol suppresses AIPC progression via inhibiting
the constitutive NF-kB activity as well as modulating the Bcl-2 family proteins.
Methodology/Principal Findings: We examined the efficacy of celastrol both in vitro and in vivo, and evaluated the role of
NF-kB in celastrol-mediated AIPC regression. We found that celastrol inhibited cell proliferation in all three AIPC cell lines
(PC-3, DU145 and CL1), with IC50 in the range of 1–2 mM. Celastrol also suppressed cell migration and invasion. Celastrol
significantly induced apoptosis as evidenced by increased sub-G1 population, caspase activation and PARP cleavage.
Moreover, celastrol promoted cleavage of the anti-apoptotic protein Mcl-1 and activated the pro-apoptotic protein Noxa. In
addition, celastrol rapidly blocked cytosolic IkBa degradation and nuclear translocation of RelA. Likewise, celastrol inhibited
the expression of multiple NF-kB target genes that are involved in proliferation, invasion and anti-apoptosis. Celastrol
suppressed AIPC tumor progression by inhibiting proliferation, increasing apoptosis and decreasing angiogenesis, in PC-3
xenograft model in nude mouse. Furthermore, increased cellular IkBa and inhibited expression of various NF-kB target
genes were observed in tumor tissues.
Conclusions/Significance: Our data suggest that, via targeting the proteasome, celastrol suppresses proliferation, invasion
and angiogenesis by inducing the apoptotic machinery and attenuating constitutive NF-kB activity in AIPC both in vitro and
in vivo. Celastrol as an active ingredient of traditional herbal medicine could thus be developed as a new therapeutic agent
for hormone-refractory prostate cancer.
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Introduction
The proteasome is a multicatalytic protease complex responsible
for the degradation of multiple intracellular proteins that are
involved in various cellular events, including DNA repair, cell
cycle, survival and apoptosis. For example, p27, a key regulator for
G1 to S transition in the cell cycle, is rapidly ubiquitinated and
degraded by proteasomes leading to p27’s short half-life [1]. Also,
most Bcl-2 family proteins are degraded by the ubiquitin-
proteasome system (UPS) [2,3,4]. Nuclear factor kappaB (NF-
kB) is an important pro-survival factor that is pivotally regulated
by the proteasome, since it is well known that in the classical NF-
kB pathway, IkBa, the sequester of NF-kB, is degraded by the
proteasome, therefore liberating NF-kB for activation [5].
Mounting evidence reveals that sustained or constitutive
activation of NF-kB contributes to malignant progression and
therapeutic resistance in most human cancers [6]. For instance, in
prostate cancer, constitutively active NF-kB has been shown to be
inversely correlated with androgen receptor status and linked to
androgen independence and therapy resistance [7]. The elevated
NF-kB surviving signaling pathway in the androgen-independent
prostate cancer (AIPC) seems to be correlated with high
proteasome activity, as reflected by a faster turnover of IkBa
[8,9]. Based on this evidence, targeting proteasomes might
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intervention. In fact, modulation of proteasomal function with
specific inhibitors has already been demonstrated as a promising
approach to treating human prostate cancer. Bortezomib
(Velcade; PS-341), the first to use a proteasome inhibitor in a
clinical application, has demonstrated anti-tumor activity when
used as a single agent or in combination with conventional
therapies in hormone-refractory prostate cancer [10]. In preclin-
ical cancer models, proteasome inhibitors induce prostate cancer
apoptosis both in vitro and in vivo [11,12], providing substantial
evidence that the proteasome inhibitors can be applied as a
therapeutic strategy for AIPC.
Celastrol is a natural proteasome inhibitor that has been reported
to show anti-proliferative effects and apoptosis in several preclinical
cancer models [12,13]. Mechanistically, NF-kB has been shown to
be a key target of celastrol [14]. Recent studies have suggested that
celastrol can enhance apoptosis and block either constitutive or
induced NF-kB activation with other therapeutic agents, such as
tumor necrosis factor [15], temozolomide [16] and gambogic acid
[17]. Furthermore, celastrol is proposed to suppress xenografted
tumor growth via targeting angiogenesis [18,19]. In the prostate
cancer setting, celastrol alone triggers apoptosis by means of
proteasome inhibition and suppresses prostate tumor growth [12].
However, the direct mechanism of action remains elusive. In the
current study, we aim to test the hypothesis that celastrol suppresses
AIPC progression via inhibiting the constitutive NF-kB activity as
well as modulating the Bcl-2 family proteins. We determined the
efficacy of celastrol both in vitro and in vivo, and evaluated the role of
NF-kB in celastrol-mediated AIPC regression.
Materials and Methods
Reagents and Cell Culture
Celastrol (98% purity) was purchased from Gaia Chemical
(Gaylordsville, CT). The powder was resolved in dimethyl
sulfoxide (DMSO) and stored as aliquots (20 mM) at 270uC.
MG-132 was purchased from BIOMOL (Plymouth Meeting, PA).
Protease inhibitor cocktail was provided by Roche (Indianapolis,
IN). Other chemicals were purchased from Sigma unless otherwise
indicated. Human prostate cancer cell lines PC-3, DU145 and
LNCaP were purchased from American Type Culture Collection.
The androgen-independent prostate cancer cell line CL1, derived
from the androgen-dependent LNCaP cell line [20], was kindly
provided by Dr. Arie Belldegrun (University of California, Los
Angeles, CA). Cells were maintained in RPMI-1640 (PC-3) or
DMEM (DU145, LNCaP and CL1) supplemented with 10% FBS,
100 U/ml penicillin, and 100 mg/ml streptomycin, and incubated
in a 5% CO2 humidified incubator at 37uC.
Cell Proliferation and Cell Death
Cells were seeded in a 96-well plate and treated with celastrol in
triplicate. After 4 days of incubation, viable cells were identified
using a cell counting kit with WST-8 (Dojindo, Rockville, MD)
and absorbance was tested at 450 nm colorimetrically. Cell
viability (%) was the ratio of absorbance of treated sample to
untreated control [21,22]. Alternatively, cells were seeded in a 24-
well plate at a density of 2610
5 cells/well and treated with
celastrol in duplicate wells. Attached cells were harvested and
counted using a Coulter cell counter (Fullerton, CA) every 24 h for
4 days. Cell death was tested by trypan blue exclusion for both
floating and attached cells [21,23]. Data were plotted and
analyzed by GraphPad Prism 5.0 (San Diego, CA). Fifty percent
inhibitory concentrations (IC50) were calculated using a sigmoidal
dose-response nonlinear regression analysis (Prism 5.0) [21,22,24].
Cell Migration
Cell migration was determined by a ‘‘wound-healing’’ assay
[25,26]. Cells were seeded in a 6-well plate and grew for 48 h to
reach confluence. Gaps were created artificially by scratching the
cell monolayer. Cell migration was photographed 6 h, 24 h and
48 h after each scratch. Cells migrating into the denuded area
were scored from four random fields.
Cell Invasion
Invasion was tested using Transwell (8 mm pore) pre-loaded
with Matrigel (BD Biosciences, San Diego, CA). Cells were
incubated with or without celastrol (1 mM) in a serum-free
medium and loaded onto the top chamber (2610
4/insert). The
complete medium (10% FBS) was added to the lower chamber to
generate a chemotractant. Twenty-four hours after cell seeding,
the inserts were wiped with a cotton swab to remove the MatriGel,
and stained with crystal violet (0.1%). Invading cells on the
underside of the filter were scored from eight random fields.
Figure 1. Celastrol inhibited prostate cancer cell proliferation.
(A): cells were treated with various doses of celastrol and cell viability
was determined by MTT assay. IC50 was shown as calculated by Prism
5.0. Data are mean 6 SD (n=3). (B): PC-3 cells were treated with
different doses of celastrol (Cel). Attached cells were harvested and
counted every day for 4 days. Data shown are mean 6 SD (n=6).
doi:10.1371/journal.pone.0014153.g001
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Cells were fixed in 70% ethanol at 4uC overnight, and then
treated with propidium iodide (PI, 50 mg/ml) and RNase A (1 mg/
ml) for 30 min. Samples were analyzed by flow cytometry
(FACScalibur, BD Biosciences). The sub-G1 population was
scored from hypodiploid DNA content [24,27]. Data were
analyzed using WinMDI 2.8 software (Purdue University Cytom-
etry Laboratory).
Caspase Activation
Cells were homogenized in a lysis buffer (BioVision, Mountain
View, CA), and whole cell lysates (40 mg) were incubated with
20 mM of fluorogenic substrate LEHD-AFC or DEVD-AFC in a
reaction buffer (BioVision) containing 5 mM DTT at 37uC for
1 h. Proteolytic release of AFC was monitored at lex=405 nm
and lem=500 nm using a fluorescence microplate reader (BMG
LABTECH, Cary, NC). Activity is expressed as ‘‘fold increase’’,
and calculated as the ratio of fluorescence signal in treated samples
to untreated control cells.
Western Blot
Whole cell lysates of cells or tumor tissues were made and
Western blot experiments were carried out as we described
previously [26]. Antibodies against poly(ADP-ribose) polymerase
(PARP) (F-2), Mcl-1 (S-19), Bcl-2 (C-2), ubiquitin (P4D1), caspase-
3 (H-277), IkBa (C-15), RelA (F-6), tubulin (4G1) and GAPDH (L-
20) were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-Noxa antibody was purchased from Calbiochem
(Gibbstown, NJ). Anti-b-actin (AC-74) antibody was obtained
from Sigma (St. Louis, MO). Band density was quantified by
TotalLab software (Durham, NC).
Subcellular Fractionation
Cytosolic and nuclear fractions were prepared as previously
described [24,25]. Briefly, cytosolic extract was obtained by
homogenizing cells in a hypotonic buffer [10 mM HEPES, 5 mM
KCl, 1.5 mM MgCl2 and 1 mM dithiothreitol (DTT) with
protease inhibitor cocktail], followed by the addition of Igepal
CA-630 (0.5%). The pellets were resolved in a hypertonic buffer
(20 mM HEPES, 50 mM KCl, 300 mM NaCl, 1 mM PMSF,
1 mM DTT, and protease inhibitors) to obtain nuclear extracts.
Subcellular proteins were quantified by Bradford assay before
Western blot.
Quantitative Real-time PCR (qPCR)
qPCR was performed to determine NF-kB target gene
expression [28]. Total RNA was extracted using TRIZOL reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. cDNA was obtained by reverse transcription with
1 mg of total RNA using a TaqMan Reverse Transcription Kit
(Applied BioSystems). SYBR Green was used for quantitative
PCR. Sequences of gene primers are listed in Table S1. Reactions
with TaqMan PCR Master Mix (Applied BioSystems) were
performed on the Mastercycler realplex
2 S system (Eppendorf,
Figure 2. Celastrol inhibited cell migration and invasion in AIPC cells. (A): PC-3 monolayer cells were scratched and treated with celastrol at
0.5 and 1 mM. ‘‘Wound-healing’’ was tested at 6 h, 24 h and 48 h post-scratch. Original magnification,6100. (B): quantification of cell migration in A
from 4 random fields in duplicate samples. Columns, mean; bars, SD (n=8). ***, P,0.001. (C): DU145 cells treated with or without 1 mM of celastrol
were seeded into Matrigel-coated transwell inserts (2610
4/insert) for 24 h. Cells on the underside of the filter were stained. Original magnification,
6200. (D): invading cells in (C) were scored from 8 random fields. Columns, mean; bars, SD (n=8). ***, P,0.001.
doi:10.1371/journal.pone.0014153.g002
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GAPDH using the formula: [2‘2(CT target2CT Actin)]6100%,
where CT is the threshold cycle [27]. mRNA expression is
expressed as ‘‘fold increase’’ and was calculated by dividing the
normalized target gene expression of the treated sample with
untreated control cells.
Animal Study
Female athymic nu/nu mice (5 weeks) were inoculated
subcutaneously (s.c.) with PC-3 cells (3610
6) on both sides of the
lower back. When tumors grew to 100 mm
3, the mice were
randomized and treated daily via oral gavage (p.o.) with vehicle
control [12] or celastrol at a dose of 1 mg/kg with 5 days per week
for 3 weeks. Tumor size was measured on the last dosing of
celastrol (day 18). Tumor volume was calculated as
(length6width
2)/2. Tumor samples were fixed in 4% paraformal-
dehyde and embedded by paraffin. Immunohistochemical analysis
was performed by Ki67, terminal deoxynucleotidyl transferase
biotin-dUTP nick end labeling (TUNEL), and CD31 staining for
the detection of proliferation, apoptosis and angiogenesis,
respectively, as we previously described [22,23,26]. All animal
experiments were carried out according to protocols approved by
University of Michigan Guidelines for Use and Care of Animals.
Statistical Analysis
Two-tailed Student’s t-test was employed for analyzing both in
vitro and in vivo data. All analysis was performed by GraphPad
Prism 5.0. A threshold of P,0.05 was defined as statistically
significant.
Results
Celastrol Inhibits Prostate Cancer Cell Proliferation
Celastrol has been reported to show anti-tumor activity in
human prostate cancer cells [12]. In our study, we confirmed that
celastrol reduced cell viability in both androgen-dependent
(LNCaP) and androgen-independent (PC-3, DU145, CL1)
prostate cancer cells, with an IC50 of cytotoxicity less than 2 mM
(Fig. 1A). For PC-3 cells, celastrol inhibited proliferation dose-
dependently (Fig. 1B), with 65% growth inhibition at the IC50 dose
(,1 mM) on day 3. At 2 mM, celastrol completely inhibited cell
growth in the cell lines tested. These data demonstrate that
Figure 3. Celastrol induced apoptosis in AIPC cells. (A): PC-3 cells were treated with celastrol for 24 h and cell cycle was tested. Cell population
in each cell cycle phase was numerically depicted. Data represent one of three independent experiments. (B): DU145 cells were treated with celastrol
(2 mM) for desired time points. Enzymatic activity of caspase-9 and caspase-3 was determined fluorometrically. Columns, mean; bars, SD (n=3).
(C): PC-3 cells were treated with celastrol with or without 1 h pretreatment of the pan-capsase inhibitor zVAD (2 mM) for Western blot analysis. Actin
was used as a loading control. Cell death was detected by trypan blue exclusion. (D): DU145 cells were treated with celastrol (2 mM) for Western blot.
Actin is a loading control.
doi:10.1371/journal.pone.0014153.g003
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viability at the concentrations ,2 mM.
Celastrol Suppresses Migration and Invasion
As a higher concentration of celastrol was cytotoxic (Fig. 1), we
evaluated the effect of celastrol on cell migration and invasion
using non-toxic doses (,1 mM). Celastrol inhibited PC-3 cell
migration in both a dose- and time-dependent manner (Fig. 2A).
With concentrations (0.5 mM) that minimally affected prolifera-
tion, celastrol prevented cell motility 24 h post-treatment
(P,0.001, Fig. 2B). Moreover, DU145 cell invasion was inhibited
to 70% by 1 mM of celastrol (P,0.001, Fig. 2C and D). These data
suggest that celastrol suppresses AIPC cell migration and invasion
at subcytotoxic concentrations.
Celastrol Induces Apoptosis and Modulates Mcl-1
We next investigated whether apoptosis is involved in celastrol-
mediated cytotoxicity. Celastrol indeed induced chromatin
condensation and DNA fragmentation in AIPC cells. PC-3 treated
with 2 mM of celastrol for 24 h produced an 8-fold increase in sub-
G1 population (Fig. 3A). In addition, celastrol induced G2/M
arrest (Fig. 3A) that was consistent with an earlier report [29],
further demonstrating celastrol’s effect on cell cycle arrest.
Celastrol also dramatically enhanced enzymatic activity of both
caspase-9 and caspase-3 in DU145, with the strongest activation
(2.960.4-fold for caspase-9 and 22.363.5-fold for caspase-3,
respectively, P,0.001) at 8 h post-treatment (Fig. 3B), indicating
the amplification of the caspase cascade in the intrinsic apoptotic
pathway. Celastrol induced PARP cleavage that could be reversed
by the pan-caspase inhibitor zVAD, demonstrating the apoptosis is
caspase-dependent (Fig. 3C). Interestingly, celastrol was shown to
simultaneously accumulate and cleave the anti-apoptotic protein
Mcl-1 at an early (4 h) rather than a late stage (24 h) in PC-3
(Fig. 3C). Such observation was consistent with the expression of
intracellular ubiquitin (Fig. 3C), suggesting a rapid and complex
regulation of Mcl-1 by the proteasome-inhibitor. In DU145, a
similar phenomenon was observed. Mcl-1 cleavage that occurred
in the early stage (4–8 h) (Fig. 3D) was correlated with caspase
activation (Fig. 3B). Furthermore, induction of cleaved Mcl-1 was
reversed by zVAD (Fig. 3C), indicating that such cleavage is
mediated by caspases. In contrast, little change was observed for
Bcl-2 (Fig. 3C), Bcl-xL or XIAP (data not shown), suggesting that
among the anti-apoptotic Bcl-2 family proteins, Mcl-1 appears to
be a major target of celastrol in the cell lines tested.
Celastrol Induces Apoptosis by Activating Noxa
It has been shown that Noxa, a BH3-only pro-apoptotic protein,
can be significantly induced by bortezomib [30]. In the current
study, we investigated whether Noxa might also be activated by
celastrol. Indeed, celastrol induced Noxa expression that was
consistent with caspase-3 activation, PARP cleavage and ubiquitin
accumulation dose-dependently in CL1 cells (Fig. 4A) and PC-3
cells (Fig. 4B). Furthermore, Noxa induction occurred as early as
2 h post-treatment, much more quickly than caspase-3 activation
and PARP cleavage in CL1 (Fig. 4C). Together, these data suggest
that Noxa is strongly and rapidly activated by celastrol, which may
be responsible for the pro-apoptotic effect in AIPC cells.
Celastrol Suppresses the Constitutive NF-kB Activity
It is well known that proteasome inhibitors, including celastrol,
can block NF-kB activity in various human cancers [15]. In our
study, we tested whether a similar result could be obtained in
AIPC cells. In PC-3 cells, celastrol blocked cytosolic IkBa
degradation, as well as nuclear translocation of NF-kB protein
RelA/p65, showing effects that exceeded MG132, a widely used
proteasome inhibitor that is shown to block NF-kB signaling [31]
(Fig. 5A). Similarly, celastrol dose-dependently caused subcellular
redistribution of NF-kB in DU145 cells (Fig. 5B). Moreover, much
like MG132, celastrol inhibited the expression of various NF-kB
target genes that are involved in multiple steps of tumor
Figure 4. Celastrol induced Noxa expression in AIPC cells.
(A): CL1 cells were treated with celastrol for 16 h. (B): PC-3 cells were
treated with celastrol (2 mM) for indicated time points. (C): CL1 cells
were treated with celastrol (2 mM) for 16 h. Whole cell lysates were
analyzed by Western blot, with Actin as a loading control.
doi:10.1371/journal.pone.0014153.g004
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D1), adhesion (ICAM-1), migration (CXCL1), invasion (MMP-9),
and anti-apoptosis (BIRC2/4/5, Bcl-2 and Bcl-xL) (Table. 1).
The inhibitory effect of NF-kB by celastrol was further confirmed
by the luciferase reporter assay (data not shown). These data
demonstrate that celastrol may suppress AIPC progression by
impeding constitutive NF-kB activity.
Anti-tumor Effect of Celastrol Involves NF-kB Attenuation
in PC-3 Xenografts
To determine whether NF-kB suppression would contribute to
tumor regression in vivo, we evaluated celastrol efficacy in the
established PC-3 xenografted model as decribed previously [26].
Treatment of celastrol (1 mg/kg) for 3 weeks inhibited PC-3 tumor
growth (P,0.05) (Fig. 6A), with a minimal systemic toxicity [26].
Histological analysis showed that celastrol reduced Ki67-positive
cells and CD31-positive microvessels, and increased TUNEL-
positive cells (Fig. 6B), suggesting that celastrol decreases
proliferation and angiogenesis, and induces apoptosis in tumor
tissues. Furthermore, total IkBa was shown to have accumulated
after treatment (Fig. 6C). Also, expression of NF-kB target genes
that are involved in proliferation (CXCL1), angiogenesis (IL-8)
and anti-apoptosis (BIRC2 and BIRC3) was inhibited by celastrol
in tumors (P,0.01 for CXCL1 and BIRC2; P,0.001 for other
genes) (Fig. 6D). These data indicate that attenuation of NF-kB
correlates with PC-3 tumor regression by celastrol in vivo.
Figure 5. Celastrol altered subcellular distribution of NF-kB in AIPC cells. (A): PC-3 cells were treated with celastrol (2 mM) or MG132
(10 mM) for 30 min. (B): DU145 cells were treated with celastrol (1 and 2 mM) for 30 min. For both (A) and (B), cells were processed for subcellular
fractionation. Cytosolic extract (CE) was probed for IkBa and nuclear extract (NE) was probed for RelA. Tubulin and PARP are used as marker and
loading control for CE and NE, respectively.
doi:10.1371/journal.pone.0014153.g005
Table 1. Summary of NF-kB target gene expression by proteasome inhibitors.
Gene DMSO Celastrol (1 mM) Celastrol (2 mM) MG132 (1 mM)
1h 2h 4h 1h 2h 4h 1h
TNF 1.0160.11 0.7860.21 0.7360.01 0.2660.03 0.3660.10 0.3060.09 0.2960.13 0.4360.13
CXCL1 1.0060.03 0.5660.04 0.4860.06 0.2260.01 0.4360.03 0.3860.04 0.3760.01 0.4360.03
c-Myc 1.0060.03 0.5960.05 0.5860.04 0.2960.02 0.4760.01 0.6260.06 0.4860.03 0.4560.02
Cyclin D1 1.0060.04 0.5260.03 0.7860.01 0.6160.03 0.5660.03 0.6860.01 0.5860.02 0.4160.01
ICAM-1 1.0160.11 0.3260.03 0.8660.08 0.5860.02 0.2560.02 0.4060.04 0.3560.07 0.3160.06
MMP9 1.0160.10 0.5860.04 0.3860.06 0.3760.05 0.3660.18 0.3860.03 0.4760.17 0.2260.02
BIRC2 1.0160.07 0.6860.08 1.2660.11 0.7060.05 0.6560.05 0.6860.07 0.8460.05 0.4860.00
BIRC4 1.0060.04 0.4360.03 0.4560.01 0.2860.02 0.3860.01 0.3660.01 0.3060.01 0.3160.01
BIRC5 1.0060.01 0.4760.03 0.5060.02 0.4660.00 0.4960.03 0.4960.02 0.4160.01 0.3460.00
Bcl-2 1.0060.06 0.5060.07 0.5660.06 0.2960.03 0.3660.01 0.5960.01 0.3160.02 0.3260.02
Bcl-xL 1.0160.08 0.6660.04 0.6660.04 0.4760.02 0.5060.01 0.6560.02 0.4860.02 0.3860.00
Note: Real-time PCR analysis of NF-kB target gene expression in PC3 cells. MG132 was used as a positive control for proteasome inhibition. Data are presented as mean
6 SEM (n=3).
doi:10.1371/journal.pone.0014153.t001
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In this study, we have found that celastrol, a natural proteasome
inhibitor, suppresses AIPC progression by modulating two
pathways. First, celastrol induces caspase-dependent apoptosis by
regulating anti-apoptotic protein Mcl-1 and activating pro-
apoptotic protein Noxa. Second, by preventing IkBa degradation,
celastrol attenuates constitutive NF-kB activity and thus abrogates
the inhibitory effect of NF-kB on apoptosis as well as the
promotion of proliferation, angiogenesis, migration and invasion
(Fig. 7). Overall, these data elucidate the potential efficacy and
mechanism of celastrol in treating AIPC via targeting the
proteasome.
It has been shown that dysregulated proteasome function is
correlated with tumor progression and therapy resistance in
human cancers [32]. Hyperactivation of NF-kB correlates with the
phenotype of androgen independence and therapy resistance in
AIPC [7,33]. In PC-3 cells, high constitutive NF-kB activity is, at
least in part, the result of a high level of proteasome activity [34].
In the current study, we report that celastrol not only potently
inhibits PC-3 growth, migration, invasion, and angiogenesis, but
also induces apoptosis that is associated with NF-kB attenuation
both in vitro and in vivo. This finding suggests that in AIPC,
suppressing NF-kB by targeting proteasome is applicable in
disrupting tumor progression, including primary growth and
metastasis. Although more evidence is needed to delineate the role
of NF-kB in celastrol-mediated tumor regression, our current
study reveals that celastrol inhibits multiple NF-kB-driven gene
expression that is involved in AIPC growth and metastasis. Our
findings, consistent with others [35,36], demonstrate that NF-kBi s
a pivotal mediator of AIPC progression, and celastrol, functioning
as an active natural proteasome inhibitor, can significantly impair
AIPC progression.
Mcl-1 is an anti-apoptotic protein in the Bcl-2 family that is
rapidly degraded by the proteasome and, therefore has a short
half-life (,3 h) [37]. An increasing number of studies propose that
proteasome inhibitors are able to reverse Mcl-1 function via
cleaving its original molecule by caspases to generate a short form
(26,28 kDa) that is pro-apoptotic regardless of the direct
stabilization of the full length of Mcl-1 [38,39]. Such rapid
turnover of Mcl-1 highlights the quick response by cancer cells
once they encounter proteasome stress, switching the phenotype
Figure 6. Celastrol suppressed PC-3 tumor progression and attenuated NF-kB activity. (A): tumor volume was measured after celastrol
treatment. The number of mice in each group was shown. *, P,0.05. (B): tumor sections were processed by anti-Ki67, TUNEL and anti-mouse CD31
staining. Original magnification, 6400. (C): whole cell lysates (50 mg) of tumor tissues were probed with anti-IkBa antibody. GAPDH was used as a
loading control. Expression fold was the ratio of IkBa expression in the celastrol group to vehicle control. (D): qPCR analysis of NF-kB target gene
expression in tumors. Total RNA from tumor tissues was extracted for reverse transcription. Gene primers were mixed with cDNA and SyberGreen for
qPCR. Columns, mean; bars, SD (n=3). **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0014153.g006
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bortezomib [38,40], we find that in AIPC, celastrol also
significantly regulates Mcl-1 at an early stage by paradoxically
accumulating the anti-apoptotic original form, while also gener-
ating the pro-apoptotic cleaved form. As cells undergo apoptosis
eventually, it is reasonable to postulate that cleaved Mcl-1 may be
more important in controlling cellular behavior than previously
reported [41]. This is because Mcl-1 cleavage occurs along with
caspase activation and before PARP cleavage, while increased
intact Mcl-1 is only a transient event in response to proteasome
inhibition. Induction of cleaved Mcl-1 can be partially attenuated
by the caspase inhibitor, suggesting that such an induction is
caspase-dependent. Interestingly, cleaved Mcl-1 levels decrease at
a later stage, which is consistent with intact Mcl-1. This suggests
that even after cleavage by caspases, the Mcl-1 fragment is still
regulated by proteasomes. Taken together, these observations
indicate that in AIPC cells, Mcl-1 is a key target of celastrol that
exhibits a complex response by proteasome inhibition.
Much like Mcl-1, Noxa is another Bcl-2 family protein that is
strongly increased by proteasome inhibition in different cancers,
including melanoma [30,42] and multiple myeloma [39,43].
However, unlike Mcl-1, Noxa is not a direct substrate of
proteasome [44]. Instead, Noxa mRNA is transcriptionally
enhanced by a proteasome inhibitor [44,45]. Noxa is a BH3-only
pro-apoptotic protein functioning in mitochondrial apoptosis
[4,22]. Upon stress, Noxa can be activated in a p53-dependent
manner and interact with anti-apoptotic proteins, thus abolishing
their negative effect on apoptosis [46]. Our results suggest that
Noxa expression occurs even before activation of the initiator
caspase-9, indicating that it is an early mediator of celastrol-
induced apoptosis. Intriguingly, none of the three AIPC cell lines
has functional p53 (PC-3 and CL1: p53 null; DU145: p53 mutant).
Thus the Noxa induction by celastrol is p53-independent. How
Noxa is positively regulated in a p53-deficient scenario is unclear.
Nevertheless, as Noxa induction correlates with Mcl-1 accumula-
tion, and since the Mcl-1/Noxa complex is reported to be
increased by bortezomib [39], current data indicate that the
potential function of the induced Noxa may be interacting with
accumulated Mcl-1 and neutralizing its anti-apoptotic effect.
Together, these data reveal that both Mcl-1 and Noxa exhibit
rapid and multi-faceted turnover events upon proteasome
inhibition, and celastrol’s coordination of these two Bcl-2 family
members will lead to apoptosis through the initiation of the
caspase cascade in AIPC.
In summary, our data outline the potent anti-tumor effects of
the traditional natural proteasome inhibitor celastrol on androgen-
independent prostate cancer. The dual role of celastrol, modulat-
ing both apoptotic proteins and NF-kB, warrants its consideration
as a potential therapeutic candidate in treating hormone-
refractory prostate cancer patients with constitutively active NF-
kB.
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